Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a S wiss cohort with obesity
Authors' conclusion
In a real-world setting, liraglutide 3.0 mg led to beneficial changes in WL and body composition, with a greater impact in women.
Study context
- Population
- Adults with BMI >35 kg/m², or BMI >28 kg/m² with ≥1 metabolic comorbidity; Switzerland; 65% women65% women
- Participants
- 54 adults
- Outcome
- Percentage weight loss (WL%) and body composition changes
- Follow-up
- 10 months
Methodological detailsreal-life setting, Liraglutide covered by Swiss health insurance
- Real-life setting
- Liraglutide covered by Swiss health insurance
Main finding
As reported in the abstract
Percentage weight loss (WL%)
Mean (SD) WL%
−12.4%
5.5%
Mean (SD) weight loss
−14.1 (6.6) kg
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Women | Men | P value |
|---|---|---|---|
| WL% by sex · 4 monthsWL% higher in women | −9.5% (SD 3.1%) | −7.2% (SD 2.5%) | P = 0.02 |
| WL% by sex · 10 monthsWL% higher in women | −13.7% (SD 5.2%) | −9.6% (SD 5.1%) | P = 0.006 |
WL% ≥5% · 4 and 10 months
- WL% ≥5% at 4 months
- 87%
- WL% ≥5% at 10 months
- 96%
Predictors of WL%
- WL% associated with baseline % fat mass but not with age or BMI
Body composition (DXA) · 10 months
- Decrease in fat mass, visceral adipose tissue and absolute lean mass
Original publication
Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a S wiss cohort with obesity. Obesity (Silver Spring). Published 7 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →